



## NEONATAL MEDICATION PROTOCOLS

**NEVIRAPINE**  
Created by: NCCU  
Date for review: Oct 2016

NCCU Clinical Guidelines  
KEMH/PMH  
Perth, Western Australia

<b>DRUG:</b>	<b>NEVIRAPINE</b>
<b>PRESENTATION:</b>	Mixture : 50mg/5mL
<b>ACTION &amp; INDICATION:</b>	Non-nucleoside reverse transcriptase inhibitor. For the treatment of HIV infection in combination with other antiviral agents. Antiretroviral regimen is decided on a case by case basis
<b>DOSE:</b>	<b>For Zidovudine, Lamivudine and Nevirapine regimen</b> 2mg/kg/dose once daily for first week of life , then 4mg/kg/dose once daily for second week of life, then stop. Other regimens may be prescribed at the Consultant's discretion
<b>ADMINISTRATION:</b>	Oral: May be given at any time with regard to feeds.
<b>ADVERSE EFFECTS:</b>	Rash, Stevens-Johnson syndrome, hepatitis, neutropenia, lymphadenopathy
<b>REFERENCES:</b>	Immunology and Infectious Diseases Departments PMH 2012 Management of infants born to HIV positive Women Neofax 2013
<b>DATE:</b>	October 2013